News
-
Two Markers of Parkinson’s Progression May Help Trials in Newly Diagnosed Patients
(April 11, 2018) – A recent study in in the journal Movement Disorders reports that clinical trials in patients with early stage Parkinson’s may benefit from assessing markers of disease progression — namely, changes in the Movement Disorder Society (M …
-
Educational Program on Medical Marijuana and Other Emerging Therapies in the Treatment of PD
(March 30, 2018) – Please join Dr. Jill Farmer on Friday, April 27, 2018 for a free educational program on Medical Marijuana and Other Emerging Therapies and Their Role in PD. The program is sponsored by Drexel Neuroscience Institute and will be held a …
-
Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film for the Treatment of OFF Episodes Associated with PD
(March 30, 2018) – Sunovion Pharmaceuticals Inc. today announced that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) on March 29, 2018, for apomorphine sublingual film (APL-130277) to treat motor fluctuatio …
-
Parkinson’s Dance Program Offered at Capital Health in central New Jersey
(March 23, 2018) – Capital Health Medical Center will be offering a Parkinson’s Dance program this spring on Thursday afternoons starting on April 5, 2018 for twelve weeks. This program is in part supported by The Parkinson Alliance. Read more for deta …
-
Informational Session for People Living with PD, ET or Dystonia and Their Caregivers
(March 22, 2018) – Robert Wood Johnson University Hospital and Drexel College of Medicine will host an informational program for people living with PD, ET or Dystonia and their caregivers on Wednesday, April 18, 2018 from 6:00-9:00pm at 3525 Quakerbrid …
-
Biomarkers Identified That Could Help Predict Individuals at Risk for Parkinson’s Disease
(March 21, 2018) – A study published in Parkinsonism & Related Disorders found that low levels of two dopamine-related molecules in cerebrospinal fluid can help identify patients in the early stages of preclinical Parkinson’s disease. Read more..
-
New Parkinson’s Collaboration Is Exactly What’s Needed, Editorial Says
(March 20, 2018) – The scope of the information on Parkinson’s research makes a collaborative effort paramount — and a U.S. government-sponsored initiative is meeting that need, according to an editorial in the journal The Lancet Neurology. The initiat …
-
Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
(March 20, 2018) – Adamas Pharmaceuticals announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without conco …
-
Nuplazid and Clozaril Are Most Reliable Parkinson’s Psychosis Therapies, Review Finds
(March 8, 2018) – The antipsychotics Nuplazid (pimavanserin) and Clozaril (clozapine) are the only therapies shown to improve Parkinson’s disease psychosis (PDP) symptoms without impairing motor function, in double-blind, placebo-controlled clinical tr …
-
NYU Langone Parkinson’s Program
(March 2, 2018) – The Center for Neuromodulation at NYU Langone Medical Center presents Knocking out Parkinson’s: Advances in PD management from Ringside to Bedside on Sunday April 15, 2018 from 1:00 – 3:00pm at NYU Langone Medical Center, FARKAS AUDIT …
